REPL vs VERA
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
REPL · Replimune$21.62 ▲ 7.99%
VERA · Vera Therapeutics$29.79 ▼ 1.18%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- REPL +148.2%
- VERA +7.3%
Head to head
| Metric | REPL | VERA |
|---|---|---|
| Price | $21.62 | $29.79 |
| Change today | ▲ 7.99% | ▼ 1.18% |
| Market cap | $2.05B | $2.15B |
| Return, 3 months | +58.2% | -5.7% |
| Return, year to date | +122.4% | -41.2% |
| Return, 1 year | +160.2% | +23.1% |
| P/E (TTM) | -7.7 | -5.0 |
| P/B | 10.0 | 6.5 |
| P/E percentile vs own 5y | 35th | 72nd |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | – |
| Net profit growth (YoY) | +31.3% | -43.0% |
| Gross margin | – | – |
| Operating margin | – | – |
| Net margin | – | – |
| Return on equity | -115.8% | -91.8% |
| Analyst target vs. price | +3.3% | +152.9% |
| Analyst buy share | 100% | 91% |
| RSI (14) | 80 | 48 |
| 30-day volatility | 90.8% | 56.6% |
| Max drawdown, 1 year | -84.2% | -52.0% |
| Trend read | Strong uptrend | Leaning bearish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- VERA is the largest of the group by market value.
- REPL has returned the most over the past year.
- REPL carries the lowest trailing P/E.
- VERA has been the calmest stock over the last 30 days.